-- Study uses Invitae Personalized Cancer Monitoring (PCM™) liquid biopsy to accurately profile tumors and enhance cancer circulating tumor DNA-based minimal residual disease (MRD) lead times; highlights promise for personalized cancer care --
PR Newswire
SAN FRANCISCO, Oct. 22, 2021